Fludarabine phosphate and melphalan: A reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect

Bone Marrow Transplantation

Volumn 37, Issue 5, 2006, Pages 455-461

  Dasgupta, Ranjit K ^a   Rule, S ^b   Johnson, P ^c   Davies, J ^c   Burnett, A ^d   Poynton, C ^d   Wilson, K ^d   Smith, G M ^e   Jackson, G ^f   Richardson, C ^f   Wareham, E ^g   Stars, A C ^g   Tollerfield, S M ^g   Morgan, G J ^h  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^b DERRIFORD HOSPITAL   (United Kingdom)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^e LEEDS GENERAL INFIRMARY   (United Kingdom)

^f ROYAL VICTORIA INFIRMARY   (United Kingdom)

^g Schering Health Care   (United Kingdom)

^h ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Allogeneic transplantation; Fludarabine phosphate; Haematological malignancy; Melphalan; Reduced intensity conditioning

Indexed keywords

CYCLOSPORIN A; FLUDARABINE PHOSPHATE; MELPHALAN; METHOTREXATE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CAUSE OF DEATH; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; DRUG DOSE REGIMEN; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVING DONOR; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NEPHROTOXICITY; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SEIZURE; SEPSIS; SEPTIC SHOCK; SURVIVAL RATE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; INFANT; MALE; MELPHALAN; MIDDLE AGED; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE PHOSPHATE;

EID: 33645276870     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705271     Document Type: Article

References (27)

1. Giralt S, Estey E, Albitar M, van Besien K, Rondón G, Anderlini P et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
2. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
3. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
4. Massenkeil G, Nagy M, Neuburger S, Tamm I, Lutz C, le Coutre P et al. Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias. Bone Marrow Transplant 2005; 36: 683-689.
5. Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russell N, de Elvira CR et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: An analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100: 4310-4316.
6. Kassim AA, Chinratanalab W, Ferrara JLM, Mineishi S. Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: 'what is the best recipe?'. Bone Marrow Transplant 2005; 36: 565-574.
7. Anderlini P, Saliba R, Acholonu S, Okoroji G-J, Donato M, Giralt S et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: Low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 2005; 35: 943-951.
8. Valcárcel D, Martino R, Caballero D, Mateos MV, Pérez-Simón JA, Canals C et al. Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 2003; 31: 387-392.
9. Mohr B, Koch R, Thiede C, Kroschinsky F, Ehninger G, Bornhäuser M. CD34+ cell dose, conditioning regimen and prior chemotherapy: Factors with significant impact on the early kinetics of donor chimerism after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2004, 34: 949-954.
10. Pérez-Simón JA, Caballero D, Diez-Campelo M, Lopez-Pérez R, Mateos G, Cañizo C et al. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia 2002; 16: 1423-1431.
11. Baron F, Baker JE, Storb R, Gooley TA, Sandmaier BM, Maris MB et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2004; 104: 2254-2262.
12. de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: Dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104: 865-872.
13. Devine SM, Sanborn R, Jessop E, Stock W, Huml M, Peace D et al. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. Bone Marrow Transplant 2001; 28: 557-562.
14. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631-637.
15. Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 2002; 30: 367-373.
16. Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulos A, Hosing C et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 2003; 102: 3052-3059.
17. van Besien K, Devine S, Wickrema A, Jessop E, Amin K, Yassine M et al. Regimen-related toxicity after fludarabine-melphalan conditioning: A prospective study of 31 patients with hematologic malignancies. Bone Marrow Transplant 2003; 32: 471-476.
18. de Lima M, Bonamino M, Vasconcelos Z, Colares M, Diamond H, Zalcberg I et al. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: High remission rate among poor prognosis patients at the expense of graft-versus-host disease. Bone Marrow Transplant 2001; 27: 73-78.
19. Gómez-Núñez M, Martino R, Caballero MD, Pérez-Simón JA, Canals C, Mateos MV et al. Elderly age and prior autologous transplantation have a deleterious effect on survival following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: Results from the Spanish multicenter prospective trial. Bone Marrow Transplant 2004; 33: 477-482.
20. Ueno NT, Cheng YC, Rondón G, Tannir NM, Gajewski JL, Couriel DR et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 2003; 102: 3829-3836.
21. Ritchie DS, Morton J, Szer J, Roberts AW, Durrant S, Shuttleworth P et al. Graft-versus-host disease, donor chimerism, and organ toxicity in stem cell transplantation after conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 2003; 9: 435-442.
22. Khouri IF, Lee MS, Saliba RM, Jun G, Fayad L, Younes A et al. Nonablative stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003; 21: 4407-4412.
23. Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96: 2419-2425.
24. Bacigalupo A. Third EBMT/AMGEN Workshop on reduced-intensity conditioning allogeneic haemopoietic stem cell transplants (RIC-HSCT), and panel consensus. Bone Marrow Transplant 2004; 33: 691-696.
25. 6/kg T cells may have an adverse effect on transplant-related mortality. Ann Hematol 2005; 84: 331-338.
26. Perez-Simon JA, Kottaridis PD, Martino R, Craddock C, Caballero D, Chopra R et al. Nonmyeloablative transplantation with or without alemtuzumab: Comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002; 100: 3121-3127.
27. Glass B, Nickelsen M, Dreger P, Claviez A, Hasenkamp J, Wulf G et al. Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells: The need for T cells early after transplantation to induce a graft-versus-lymphoma effect. Bone Marrow Transplant 2004; 34: 391-397.